Top Analyst Reports for Abbott, BP & Gilead

21.06.24 22:24 Uhr

Werte in diesem Artikel

92,07 EUR -1,68 EUR -1,79%

5,44 EUR -0,01 EUR -0,18%

66,48 EUR -1,31 EUR -1,93%



8.155,7 PKT -49,2 PKT -0,60%

4.473,4 PKT -28,0 PKT -0,62%

19.522,6 PKT -182,5 PKT -0,93%

17.726,9 PKT -144,3 PKT -0,81%

7.458,3 PKT -63,3 PKT -0,84%

15.716,7 PKT -210,8 PKT -1,32%

2.661,5 PKT -20,7 PKT -0,77%

1.854,4 PKT -8,4 PKT -0,45%

5.505,0 PKT -39,6 PKT -0,71%

4.415,4 PKT -26,8 PKT -0,60%

Friday, June 21, 2024The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories (ABT), BP p.l.c. (BP) and Gilead Sciences, Inc. (GILD), as well as two micro-cap stocks Smith-Midland Corp. (SMID) and Crimson Wine Group, Ltd. (CWGL). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>>Shares of Abbott have declined -1.5% over the past year against the Zacks Medical - Products industry’s decline of -1.6%. The company’s pipeline is generating several new growth prospects, which will help sustain the positive momentum and contribute to the strong growth projection in 2024.Alinity, the company’s next-generation suite of systems, is a key driver in the core lab diagnostics business. EPD's impressive stretch of strong performance stems from the company’s unique business model. Freestyle Libre CGM device is also on a great trajectory, continually outpacing market growth.Within Nutrition, after a period of hiccups, Abbott has finally reestablished itself as the market leader in the infant formula business, underscoring strong customer confidence in the company's products. However, the slump in COVID-19 testing-related sales is hurting Abbott’s overall growth. Tough macro conditions also pose a concern for its operations.(You can read the full research report on Abbott here >>>)BP’s shares have gained +1.4% over the past year against the Zacks Oil and Gas - Integrated - International industry’s gain of +6.6%. The company has a strong portfolio of upstream projects, supporting notable growth in production. The integrated energy company exhibits robust upstream growth with the start-up of major projects like Seagull, which boosts its production capacity.Diversification into renewables through the Lightsource BP acquisition supports long-term sustainability amid energy transitions. The divestment strategy aims to reach $25 billion by 2025, enhancing the balance sheet and returning capital to shareholders.However, a high debt-to-capitalization ratio raises financial flexibility and balance sheet concerns. Also, despite resolving significant litigation expenses from the 2010 oil spill, BP had to sell valuable assets. These divestitures could potentially limit future cash generation. Refining margins may face pressure due to narrower crude differentials.(You can read the full research report on BP here >>>)Shares of Gilead have declined -8.6% over the past year against the Zacks Medical - Biomedical and Genetics industry’s decline of -11.2%. The company's recent pipeline setbacks weigh on its balance sheet. Gaining incremental market share is likely to get tougher due to the competition in the HIV market.Nevertheless, Gilead’s flagship HIV therapy, Biktarvy, continues to maintain its strong growth, thereby fueling the top line. The approval of new therapies has boosted the company’s market-leading HIV franchise. Gilead’s efforts to develop better HIV treatments are commendable.Substantial growth in Yescarta and Tecartus, and the strong uptake of Trodelvy have strengthened its oncology franchise. Gilead's efforts to bolster its oncology and virology franchises through internal pipeline development and collaborations are encouraging.(You can read the full research report on Gilead here >>>)Smith-Midland’s shares have outperformed the Zacks Building Products - Concrete and Aggregates industry over the past year (+71.7% vs. +14.7%). This microcap company with market capitalization of $174.47 million hit a record $59.6 million in 2023, up 19% year over year due to expanded sales of soundwalls and barrier rentals, supported by strategic manufacturing investments and a global licensee network.Operational efficiency improved, turning a prior year operating loss into a $542,000 operating income in fourth-quarter 2023. Infrastructure spending tailwinds from the Infrastructure and Jobs Act may boost the 2024 results. Financial health is strong, with $9.2 million in cash and $5 million invested in production capacity.However, rising material and labor costs, high receivables, and intense competition pose risks. The dependence on key customers and potential regulatory penalties could impact SMID’s financials. The possibility of reduced government infrastructure spending could further strain performance.(You can read the full research report on Smith-Midland here >>>)Shares of Crimson Wine have declined -2.3% over the past year against the Zacks Beverages - Alcohol industry’s decline of -12.3%. This microcap company with market capitalization of $119.88 million boasts a strong portfolio of seven luxury wine brands, appealing to affluent consumers with wines retailing more than $16 per 750 ml bottle. It has a healthy balance sheet, with $22.6 million in cash and a current ratio of 10.3.Continued investment in premium brands and a robust inventory of 0.7 million cases position the company well. CWGL has a $60-million credit facility with no drawdowns, reflecting financial flexibility and an improved gross margin. Yet, Crimson Wine Group reported first-quarter net loss of $633,000, with rising operating expenses outpacing revenue growth.High inventory levels suggest misalignment with market demand. Climate change and adverse weather pose risks to grape quality and production costs. Also, CWGL faces technological and cybersecurity risks with its new ERP system and inflationary pressures.(You can read the full research report on Crimson Wine here >>>)Other noteworthy reports we are featuring today include Constellation Brands, Inc. (STZ), D.R. Horton, Inc. (DHI) and Waste Connections, Inc. (WCN).Mark VickerySenior EditorNote: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>Today's Must ReadAbbott (ABT) Banks on Nutrition Arm, Solid Libre ProspectBP's Robust Upstream Portfolio to Boost Production CapacityHIV, Oncology Fuel Gilead (GILD) Amid Pipeline SetbacksFeatured ReportsBrand Building Boosts Constellation Brands' (STZ) Market SharePer the Zacks analyst, Constellation Brands' consistent focus on brand building and inclusion of new products are key revenue drivers. This helped boost market share, mostly in the U.S. beer category.D.R. Horton's (DHI) Affordable Homes Aid, High Rates AilD.R. Horton to gain from its robust backlog, industry-leading market share, acquisitions and focus on more entry-level affordable homes, per the Zacks analyst. Yet, higher rates are concerns.Operating Prowess Aid Waste Connections (WCN), Liquidity LowPer the Zacks analyst, Waste Connections' low-overhead, highly efficient operational structure allows it to expand into geographically contiguous markets. Low liquidity remains a concern.Darden (DRI) Banks on Unit Growth & Digitization, Costs HighPer the Zacks analyst, Darden is likely to benefit from new restaurant openings, the integration of Ruth's Chris Steak House and digital efforts. However, commodity and wage inflation is a concern.Strength in Aerospace, Industrial Sectors Aids Woodward (WWD)Per the Zacks analyst, momentum across Aerospace and Industrial segments is cushioning Woodward's top-line performance. The Industrial unit is expected to gain from higher demand for power generation.Rayonier (RYN) Rides on Solid Portfolio Amid High RatesPer the Zacks analyst, a solid timberland portfolio and unlocking the long-term value of its HBU development and rural property portfolio are likely to support Rayonier despite high interest rates.Rising Production Aids SolarEdge (SEDG), Lower Demand WoesPer the Zacks analyst, growing production capacity and steady inverter shipments is likely to boost SolarEdge's revenues. Yet, lower installation in Europe might adversely impact its overall growth.New UpgradesPackaging Demand, Cost Savings Actions Aid WestRock (WRK)Per the Zacks analyst, WestRock will gain from stable packaging demand in the food, beverage, and e-commerce sectors. Pricing strategies and cost-saving measures will help improve its margins.Sprouts Farmers' (SFM) Omnichannel Offering to Propel SalesPer the Zacks analyst Sprouts Farmers' assortment of better-for-you products, focus on providing hassle-free shopping through omnichannel offering and a network of fresh distribution centers bode wellGrowing Top Line, Solid Capital Position Aid Palomar (PLMR)Per the Zacks analyst, Palomar's growing revenues driven by higher premiums and net investment income have led to significant growth. Moreover, robust capital position supports capital deployment.New DowngradesLower IT Spending to Hurt Avnet's (AVT) Growth ProspectsPer the Zacks Analyst, Avnet's growth prospects might be hurt by soft IT spending as organizations are pushing back their large IT investment plans amid the macroeconomic headwinds.Lower Steel Prices, High Debt Ail Nucor (NUE)Per the Zacks analyst, the company faces margin headwinds from a significant decline in steel prices due to a slowdown in end-market demand. A high debt level is also a concern. Declining Premiums, Soft Cash Flows Hurt Amerisafe (AMSF)Per the Zacks analyst, product concentration and constrained premiums are hurting Amerisafe's top-line growth. A decline in operating cash flows remains a concern.Buy 5 Stocks BEFORE Election DayBiden or Trump? Zacks is releasing a FREE Special Report, Profit from the 2024 Presidential Election (no matter who wins).Since 1950, presidential election years have been strong for the market. This report names 5 timely stocks to ride the wave of electoral excitement.They include a medical manufacturer that gained +11,000% in the last 15 years… a rental company absolutely crushing its sector… an energy powerhouse planning to grow its already large dividend by 25%... an aerospace and defense standout that just landed a potentially $80 billion contract… and a giant chipmaker building huge plants in the U.S. Don’t Wait. Download FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report BP p.l.c. (BP): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Constellation Brands Inc (STZ): Free Stock Analysis Report D.R. Horton, Inc. (DHI): Free Stock Analysis Report Waste Connections, Inc. (WCN): Free Stock Analysis Report Smith-Midland Corp. (SMID): Get Free Report Crimson Wine Group Ltd. (CWGL): Get Free ReportTo read this article on click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Abbott Laboratories

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Abbott Laboratories


Quelle: Zacks

Nachrichten zu BP plc (British Petrol)

Analysen zu BP plc (British Petrol)

10.07.2024BP BuyGoldman Sachs Group Inc.
10.07.2024BP UnderweightJP Morgan Chase & Co.
09.07.2024BP BuyJefferies & Company Inc.
09.07.2024BP OutperformRBC Capital Markets
09.07.2024BP BuyUBS AG
10.07.2024BP BuyGoldman Sachs Group Inc.
09.07.2024BP BuyJefferies & Company Inc.
09.07.2024BP OutperformRBC Capital Markets
09.07.2024BP BuyUBS AG
03.07.2024BP OutperformRBC Capital Markets
13.05.2024BP HoldJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
22.02.2024BP HoldJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
06.02.2024BP HoldJefferies & Company Inc.
17.01.2024BP HoldJefferies & Company Inc.
29.11.2023BP HoldJefferies & Company Inc.
10.07.2024BP UnderweightJP Morgan Chase & Co.
09.07.2024BP UnderweightJP Morgan Chase & Co.
16.05.2024BP UnderweightJP Morgan Chase & Co.
24.04.2024BP UnderweightJP Morgan Chase & Co.
09.04.2024BP UnderweightJP Morgan Chase & Co.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für BP plc (British Petrol) nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"